跳至主要内容
临床试验/NCT06430047
NCT06430047招募中4 期

The Role of an EsoDuo® to Control Reflux Symptoms Related to the Acid; a Multicenter, Open-labeled, Phase 4 Study [RACER Study]

Chong Kun Dang Pharmaceutical1 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2022年11月25日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
180
试验地点
1
主要终点
The time taken to control the symptoms of GERD

研究概览

简要总结

Clinical Trial to Evaluate the Effects of EsoDuo® in Controlling Reflux Symptoms Related to the Acid

详细描述

The Role of an EsoDuo® to Control Reflux Symptoms Related to the Acid; a Multicenter, Open-labeled, Phase 4 Study [RACER Study]

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or Female aged ≥ 19 years
  • Patients diagnosed with non-erosive reflux disease or mild erosive reflux disease
  • Episode of heartburn the GERD symptom(either heartburn or gastric acid reflux)

排除标准

  • Surgery history on stomach or esophagus
  • Barrett's esophagus (over 3cm), esophageal varices, esophageal stricture, esophageal achalasia, eosinophilic esophagitis, and primary motility disorders
  • Patients diagnosed with Grade C or Grade D according to the LA Classification system during upper gastrointestinal endoscopy
  • Patients with a history of malignancy within the past 5 years prior to the screening visit (Visit 1)
  • Patients who have taken prohibited concomitant medications within 14 days prior to the screening visit or require continuous administration of prohibited medications during the trial period.
  • Clinically significant Abnormal Lab test
  • Pregnant woman, Breastfeeding woman.

研究组 & 干预措施

Experimental Group

Experimental

干预措施: EsoDuo® Tablet (Drug)

结局指标

主要结局

The time taken to control the symptoms of GERD

时间窗: 2 weeks after the clinical trial participation

the symptoms of GERD : heartburn or acid reflux

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Efficacy and Safety of EsoDuo® | 临床试验